ZA200800999B - Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy - Google Patents

Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy

Info

Publication number
ZA200800999B
ZA200800999B ZA200800999A ZA200800999A ZA200800999B ZA 200800999 B ZA200800999 B ZA 200800999B ZA 200800999 A ZA200800999 A ZA 200800999A ZA 200800999 A ZA200800999 A ZA 200800999A ZA 200800999 B ZA200800999 B ZA 200800999B
Authority
ZA
South Africa
Prior art keywords
prophylaxis
treatment
muscular dystrophy
omigapil
ynylamine
Prior art date
Application number
ZA200800999A
Other languages
English (en)
Inventor
Meier Thomas
Markus A Rueegg
Original Assignee
Ch Santhera Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ch Santhera Pharmaceuticals Ag filed Critical Ch Santhera Pharmaceuticals Ag
Publication of ZA200800999B publication Critical patent/ZA200800999B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
ZA200800999A 2005-08-25 2008-01-30 Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy ZA200800999B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05018530A EP1757284A1 (en) 2005-08-25 2005-08-25 Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy

Publications (1)

Publication Number Publication Date
ZA200800999B true ZA200800999B (en) 2008-11-26

Family

ID=35207868

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800999A ZA200800999B (en) 2005-08-25 2008-01-30 Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy

Country Status (17)

Country Link
US (1) US7999002B2 (xx)
EP (2) EP1757284A1 (xx)
JP (1) JP4852100B2 (xx)
AT (1) ATE485820T1 (xx)
AU (1) AU2006284140B2 (xx)
CA (1) CA2620891C (xx)
CY (1) CY1111067T1 (xx)
DE (1) DE602006017855D1 (xx)
DK (1) DK1924255T3 (xx)
ES (1) ES2351577T3 (xx)
MX (1) MX2008002563A (xx)
NZ (1) NZ565194A (xx)
PL (1) PL1924255T3 (xx)
PT (1) PT1924255E (xx)
SI (1) SI1924255T1 (xx)
WO (1) WO2007022951A1 (xx)
ZA (1) ZA200800999B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1842539A1 (en) * 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
JP6819337B2 (ja) * 2017-02-10 2021-01-27 セイコーエプソン株式会社 印刷装置、及び、印刷装置の制御方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780244A (en) * 1993-09-27 1998-07-14 La Jolla Cancer Research Foundation Changes in laminin subunit composition are diagnostic of Fukuyama congenital muscular dystrophy
US5863743A (en) * 1994-08-12 1999-01-26 University Of Iowa Research Foundation Merosin deficiency-type congenital muscular dystrophy
EP0726265B1 (de) * 1995-02-08 2001-07-25 Novartis AG Antineurodegenerativ wirksame 10-Aminoaliphatyl-dibenz- b,f oxepine
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
DZ3083A1 (fr) * 1999-02-19 2004-06-02 Smithkline Beecham Corp Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
US7563862B2 (en) * 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
US7078379B2 (en) * 2002-06-03 2006-07-18 Santhera Pharmaceuticals (Schweiz) Gmbh Treatment of congenital muscular dystrophies
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
TW200505435A (en) 2003-01-29 2005-02-16 Novartis Ag Treatment of ocular disorders
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US8043614B2 (en) * 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
AR046320A1 (es) 2003-11-06 2005-11-30 Novartis Ag Composiciones farmaceuticas estabilizadas de dibenzo-oxepina.
EP1842539A1 (en) * 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency

Also Published As

Publication number Publication date
MX2008002563A (es) 2008-03-25
AU2006284140B2 (en) 2009-08-20
WO2007022951A1 (en) 2007-03-01
EP1924255B1 (en) 2010-10-27
ATE485820T1 (de) 2010-11-15
CA2620891C (en) 2010-11-09
US7999002B2 (en) 2011-08-16
DE602006017855D1 (de) 2010-12-09
JP4852100B2 (ja) 2012-01-11
DK1924255T3 (da) 2011-01-31
PT1924255E (pt) 2010-11-08
US20100160269A1 (en) 2010-06-24
NZ565194A (en) 2010-04-30
SI1924255T1 (sl) 2011-02-28
JP2009505998A (ja) 2009-02-12
CY1111067T1 (el) 2015-06-11
AU2006284140A1 (en) 2007-03-01
EP1757284A1 (en) 2007-02-28
PL1924255T3 (pl) 2011-09-30
EP1924255A1 (en) 2008-05-28
ES2351577T3 (es) 2011-02-08
CA2620891A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
HK1152705A1 (en) Dihydropyrimidine compounds and use thereof for the treatment of viral diseases
HK1111083A1 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
TW200728307A (en) Novel spirochromanone derivatives
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
GB0516168D0 (en) Pharmaceutical compounds
WO2008142055A3 (en) Antiviral agents
TW200626158A (en) Naphthaline derivatives
MX2010008921A (es) Derivados de oxazolidinona.
WO2010066629A3 (en) Novel azaindoles
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
IL172290A0 (en) Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
UA92586C2 (ru) Лечение или предотвращение респираторных вирусных инфекций с помощью иммуномодуляторов
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
ZA200800999B (en) Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2004035031A3 (en) Treatment of uveal melanoma